NEW YORK – Microbial detection startup MantaBio said on Tuesday that it has raised $2.5 million in seed funding from undisclosed investors to help develop its qPCR-based microbial contamination testing platform for biopharma applications.

纽约——微生物检测初创公司MantaBio周二表示，已从未披露的投资者处筹集了250万美元的种子资金，以帮助开发其基于qPCR的生物制药应用微生物污染检测平台。

In an email, MantaBio Chief Operating Officer Carter Boisfontaine said the company plans to use the money raised to fund team growth, R&D, and pharma partnerships.

在一封电子邮件中，MantaBio 首席运营官卡特·布瓦丰坦表示，公司计划利用筹集到的资金推动团队扩张、研发以及制药合作。

Founded in 2025, the Beverly, Massachusetts-based company is developing a real-time PCR platform named MantaVision that is 'explicitly and exclusively' designed for automated microbial contamination detection for biopharma applications, Boisfontaine noted.

Boisfontaine 指出，这家总部位于马萨诸塞州贝弗利的公司成立于 2025 年，正在开发一个名为 MantaVision 的实时 PCR 平台，该平台“明确且专为”生物制药应用中的自动化微生物污染检测而设计。

According to Boisfontaine, MantaVision is being designed to accommodate a wide range of sample inputs, from 1 mL to 10mL, and to be 'extremely easy to use' due to automation. The company promises that MantaVision will deliver results from samples in just two hours.

根据布瓦斯方的说法，MantaVision 的设计可容纳从 1 毫升到 10 毫升的广泛样本输入，并且由于自动化程度高，将“极其易于使用”。该公司承诺 MantaVision 将在短短两个小时内提供样本结果。